S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

MNKD MannKind Corporation

4.30

-0.04 (-0.92%)

After Hours

Last Updated: 17:44:02

Delayed by 15 minutes

MannKind prices upsized $200M convertible debt offering

To read the full story on Seeking Alpha, click here.

MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more MannKind Charts.

MannKind (NASDAQ:MNKD)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more MannKind Charts.

MannKind Corporation News

MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
Wednesday 1 May 2024 (1 day ago) • GlobeNewswire Inc.

MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
Tuesday 30 April 2024 (3 days ago) • GlobeNewswire Inc.

MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
Monday 29 April 2024 (4 days ago) • GlobeNewswire Inc.

MannKind Repays Certain Debt Obligations
Wednesday 3 April 2024 (4 weeks ago) • GlobeNewswire Inc.

MannKind Announces CFO Transition
Tuesday 26 March 2024 (1 month ago) • GlobeNewswire Inc.

INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
Monday 11 March 2024 (2 months ago) • GlobeNewswire Inc.

MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
Tuesday 5 March 2024 (2 months ago) • GlobeNewswire Inc.

MannKind Corporation Announces Participation at Upcoming Conferences
Monday 4 March 2024 (2 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 27 February 2024 (2 months ago) • Edgar (US Regulatory)

MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
Tuesday 27 February 2024 (2 months ago) • GlobeNewswire Inc.

MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
Tuesday 20 February 2024 (2 months ago) • GlobeNewswire Inc.

MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
Thursday 15 February 2024 (3 months ago) • GlobeNewswire Inc.

More MannKind Corporation News Articles

Globestar Therapeutics (PK)

BlackStar Enterprise (PK)

Therapeutic Solutions (PK)

International Star (PK)

Voip Pal Com (QB)

Atacama Resources (PK)

Trump Media and Technology

Brookmount Explorations (PK)

MicroCloud Hologram

Mullen Automotive

FBEC Worldwide (PK)

Verb Technology

Buildablock (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions